Objective
ENLIGHT-TEN is a European Network Linking Informatics and Genomics of Helper T cells: our mission is to provide cross-disciplinary training in cellular immunology and big data analysis such that we train a new generation of researchers to fully exploit the power of emerging technological platforms. Our network of TEN beneficiaries combines T cell expertise with state-of-the-art technologies such as next generation sequencing (NGS), bioinformatics, multi-colour flow cytometry, preclinical models and tailored genome editing. Trainees will acquire a comprehensive knowledge in T cell immunology and the capacity to generate and interrogate big data sets as well as expertise in identifying novel biomarkers and developing therapeutic concepts. As such the training programme will provide an ideal stepping-stone for creative and innovative early stage researchers (ESRs) to enter and strengthen Europe’s academia as well as pharmaceutical and bioinformatics companies.
The research focus of the network lies in the identification of extrinsic and intrinsic factors that control development, differentiation and plasticity of helper T cell subsets with particular emphasis on how T cell differentiation impacts on human diseases. The generation of large data sets is an emerging and challenging field, and there is high demand in both the academic sector as well as pharmaceutical companies for researchers to be able to analyse, integrate and exploit this rich source of information. ENLIGHT-TEN will combine the individual strengths of innovative laboratories and enterprises from complementary disciplines to provide unique interdisciplinary training for 13 ESRs, placing them at the forefront of this emerging field. Trainees will be empowered to perform cutting-edge analysis of the steadily increasing number of different T cell subsets, which play highly diverse and critical roles in the development of autoimmune diseases, making them a key target for pharmaceutical companies.
Fields of science
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- natural sciencescomputer and information sciencesdata sciencebig data
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health sciencesbasic medicinepathology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Programme(s)
Coordinator
38124 Braunschweig
Germany
See on map
Participants (11)
WC1E 6BT London
See on map
1090 Wien
See on map
Participation ended
13353 Berlin
See on map
Participation ended
69117 Heidelberg
See on map
1649 028 Lisboa
See on map
CB22 3AT Cambridge
See on map
20014 Turku
See on map
75654 Paris
See on map
8000 Aarhus
See on map
CB10 1SA SAFFRON WALDEN
See on map
51373 Leverkusen
See on map
Partners (6)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1030 Wien
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
SG1 2FX Stevenage
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
CB10 1DR Cambridge
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
80335 Muenchen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1228 Plan Les Ouates Geneve
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.